Systematic Review

MiRNA expression profiling in HIV pathogenesis, disease progression and response to treatment: a systematic review

https://orcid.org/0000-0002-1357-4578

Institute of Clinical Physiology National Research Council, Branch of Lecce, 73100, Italy

‡Authors contributed equally

Search for more papers by this author

Pierpaolo Mincarone^‡

https://orcid.org/0000-0002-8452-5642

Institute for Research on Population & Social Policies National Research Council, Research Unit of Brindisi, 72100, Italy

‡Authors contributed equally

Search for more papers by this author

Maria Rosaria Tumolo

*Author for correspondence: Tel.: +39 389 011 8275;

E-mail Address: mariarosaria.tumolo@irpps.cnr.it

https://orcid.org/0000-0002-8396-4731

Institute for Research on Population & Social Policies National Research Council, Research Unit of Brindisi, 72100, Italy

Search for more papers by this author

Alessandra Panico

https://orcid.org/0000-0002-1876-7184

University of Salento, Department of Biological & Environmental Sciences & Technologies, Lecce, 73039, Italy

Search for more papers by this author

Marcello Guido

https://orcid.org/0000-0002-7907-2677

University of Salento, Department of Biological & Environmental Sciences & Technologies, Lecce, 73039, Italy

Search for more papers by this author

Antonella Zizza

https://orcid.org/0000-0001-5598-8499

Institute of Clinical Physiology National Research Council, Branch of Lecce, 73100, Italy

Search for more papers by this author

Roberto Guarino

https://orcid.org/0000-0002-0127-6557

Institute of Clinical Physiology National Research Council, Branch of Lecce, 73100, Italy

Search for more papers by this author

Giuseppe De Santis

Department of Neurology, Card. G. Panico Hospital, Tricase, 73039, Italy

Search for more papers by this author

Raffaella Sedile

Institute of Clinical Physiology National Research Council, Branch of Lecce, 73100, Italy

Search for more papers by this author

Saverio Sabina

https://orcid.org/0000-0002-5337-2356

Institute of Clinical Physiology National Research Council, Branch of Lecce, 73100, Italy

Search for more papers by this author

Published Online:25 Oct 2021https://doi.org/10.2217/epi-2021-0237

View article

Abstract

Aim: A systematic review was conducted to identify the association of miRNA expression with HIV pathogenesis, progression and treatment. Methods: A search of articles was conducted in MEDLINE^®, Cochrane Central Register of Controlled Trials and Global Health. Results: 35 articles were included. Due to the heterogeneity of HIV phenotypes, a harmonization based on key progression parameters was proposed. The hsa-miR-29 family, hsa-miR-146b-5p and hsa-miR-150-5p, are the most frequently differentially expressed in HIV. Direct comparison of studies was not possible due to heterogeneity in biological samples and miRNA analysis techniques. Conclusion: This is the first attempt to systematically identify miRNA's different expression in well-defined patient phenotypes and could represent a helpful way to increase general knowledge in this field.

Lay abstract

miRNAs play important role in the regulation of gene expression and are involved in various physiological processes. Dysregulation of their function can lead to human diseases including cancer, cardiovascular and metabolic diseases, liver conditions and immune dysfunction. The aim of this work is to systematically analyze the current scientific literature to identify miRNAs linked to the mechanism, development and treatment of HIV. A total of 35 articles were included and the miRNAs that were found with significantly different levels in compared groups of subjects (e.g., subjects with HIV vs healthy persons, persons able to limit the disease progression without therapy vs those whose immune system is already compromised by HIV) were highlighted. The most frequently reported miRNAs were: the hsa-miR-29 family, hsa-miR-146b-5p and hsa-miR-150-5p. To our knowledge, this is the first attempt to systematically identify the miRNAs associated with HIV and could be a useful contribution to general knowledge in this field.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Sierra S, Kupfer B, Kaiser R. Basics of the virology of HIV-1 and its replication. J. Clin. Virol. 34(4), 233–244 (2005).
Medline CASGoogle Scholar
2. Langebeek N, Kooij KW, Wit FW et al. Impact of comorbidity and ageing on health-related quality of life in HIV-positive and HIV-negative individuals. AIDS 31(10), 1471–1481 (2017).
MedlineGoogle Scholar
3. WHO. Number of people (all ages) living with HIV (2019). https://apps.who.int/gho/data/node.main.620?lang=en
Google Scholar
4. Eggleton JS, Nagalli S. Highly active antiretroviral therapy (HAART). In: StatPearls [Internet]. StatPearls Publishing, FL, USA (2021).
Google Scholar
5. Oguntibeju O. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS Res. Palliat. Care 4, 117 (2012).
Google Scholar
6. Deeks SG, Lewin SR, Ross AL et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat. Med. 22(8), 839–850 (2016).
Medline CASGoogle Scholar
7. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir. Ther. 18(1), 115–123 (2012).
MedlineGoogle Scholar
8. Le Douce V, Janossy A, Hallay H et al. Achieving a cure for HIV infection: do we have reasons to be optimistic? J. Antimicrob. Chemother. 67(5), 1063–1074 (2012).
MedlineGoogle Scholar
9. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 20(8), 460–469 (2014).
Medline CASGoogle Scholar
10. Qu Z, Li W, Fu B. MicroRNAs in autoimmune diseases. Biomed Res. Int. 2014, 1–8 (2014).
Google Scholar
11. Maciotta S, Meregalli M, Torrente Y. The involvement of microRNAs in neurodegenerative diseases. Front. Cell Neurosci. 7, 265 (2013).
Medline CASGoogle Scholar
12. Mi S, Zhang J, Zhang W, Huang RS. Circulating microRNAs as biomarkers for inflammatory diseases. MicroRNA 2(1), 64–72 (2013).
CASGoogle Scholar
13. Tumolo MR, Panico A, De Donno A et al. The expression of microRNAs and exposure to environmental contaminants related to human health: a review. Int. J. Environ. Health Res. 12, 1–23 (2020).
Google Scholar
14. Panico A, Tumolo MR, Leo CG et al. The influence of lifestyle factors on miRNA expression and signal pathways: a review. Epigenomics 13(2), 145–164 (2021).
CASGoogle Scholar
15. Sun G, Rossi JJ. MicroRNAs and their potential involvement in HIV infection. Trends Pharmacol. Sci. 32(11), 675–681 (2011).
Medline CASGoogle Scholar
16. Lenkala D, LaCroix B, Gamazon ER, Geeleher P, Im HK, Huang RS. The impact of microRNA expression on cellular proliferation. Hum. Genet. 133(7), 931–938 (2014).
Medline CASGoogle Scholar
17. Schickel R, Boyerinas B, Park S-M, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27(45), 5959–5974 (2008).
Medline CASGoogle Scholar
18. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol. Rev. 91(3), 827–887 (2011).
Medline CASGoogle Scholar
19. Su Z, Yang Z, Xu Y, Chen Y, Yu Q. MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget 6(11), 8474–8490 (2015).
MedlineGoogle Scholar
20. Lindsay MA. microRNAs and the immune response. Trends Immunol. 29(7), 343–351 (2008).
Medline CASGoogle Scholar
21. Gottwein E. Roles of microRNAs in the life cycles of mammalian viruses. Curr. Topics Microbiol. Immunol. 371, 201–227 (2013).
Medline CASGoogle Scholar
22. Tam S, de Borja R, Tsao M-S, McPherson JD. Robust global microRNA expression profiling using next-generation sequencing technologies. Lab. Investig. 94(3), 350–358 (2014).
Medline CASGoogle Scholar
23. Sadri Nahand J, Bokharaei-Salim F, Karimzadeh M et al. MicroRNAs and exosomes: key players in HIV pathogenesis. HIV Med. 21(4), 246–278 (2020). • Reports miRNAs as important players in HIV pathogenesis with potential diagnostic applications as biomarkers in HIV infection.
MedlineGoogle Scholar
24. Wallace BC, Small K, Brodley CE, Lau J, Trikalinos TA. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr. Presented at: ACM Int. Health Informat. Symposium (IHI). FL, USA, 28 – 30 January 2012.
Google Scholar
25. Hyland Software. Alfresco – ECM and BPM Software | Alfresco (2021). www.alfresco.com/
Google Scholar
26. Gurdasani D, Iles L, Dillon DG et al. A systematic review of definitions of extreme phenotypes of HIV control and progression. AIDS 28(2), 149–162 (2014). • Gives evidence of the heterogeneity in HIV phenotypes that may represent important differences in biological phenotypes and clinical progression profiles of individuals and suggests the need for harmonized definitions.
MedlineGoogle Scholar
27. Okulicz JF, Marconi VC, Landrum ML et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J. Infect. Dis. 200(11), 1714–1723 (2009).
MedlineGoogle Scholar
28. Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 47(D1), D155–D162 (2019).
Medline CASGoogle Scholar
29. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42(D1), D68–D73 (2014).
Medline CASGoogle Scholar
30. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39 (Database), D152–D157 (2011).
Medline CASGoogle Scholar
31. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res. 36 (Database), D154–D158 (2007).
MedlineGoogle Scholar
32. Griffiths-Jones S. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34 (90001), D140–D144 (2006).
Medline CASGoogle Scholar
33. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 32(90001), 109D–111 (2004).
Google Scholar
34. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700 (2009).
MedlineGoogle Scholar
35. Dweep H, Gretz N, Sticht C. miRWalk database for miRNA-target interactions. Methods Mol. Biol. 1182, 289–305 (2014).
MedlineGoogle Scholar
36. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics 16(1), 169 (2015).
MedlineGoogle Scholar
37. Su G, Morris JH, Demchak B, Bader GD. Biological network exploration with Cytoscape 3. Curr. Protoc. Bioinforma. 47, 8.13.1–24 (2014).
MedlineGoogle Scholar
38. Noorbakhsh F, Ramachandran R, Barsby N et al. MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J. 24(6), 1799–1812 (2010).
Medline CASGoogle Scholar
39. Jin C, Cheng L, Höxtermann S et al. MicroRNA-155 is a biomarker of T-cell activation and immune dysfunction in HIV-1-infected patients. HIV Med. 18(5), 354–362 (2017).
Medline CASGoogle Scholar
40. Rosca A, Anton G, Botezatu A et al. miR-29a associates with viro-immunological markers of HIV infection in treatment experienced patients. J. Med. Virol. 88(12), 2132–2137 (2016). • Reports an association between miR-29a expression levels and the virological and immunological markers of HIV-1 infection in antiretroviral treatment-experienced patients.
Medline CASGoogle Scholar
41. Zhou L, Pupo GM, Gupta P et al. A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. BMC Genomics 13, 677 (2012).
Medline CASGoogle Scholar
42. Bignami F, Pilotti E, Bertoncelli L et al. Stable changes in CD4⁺ T lymphocyte miRNA expression after exposure to HIV-1. Blood 119(26), 6259–6267 (2012).
Medline CASGoogle Scholar
43. Dey R, Soni K, Saravanan S et al. Anti-HIV microRNA expression in a novel Indian cohort. Sci. Rep. 6, 28279 (2016).
Medline CASGoogle Scholar
44. Egana-Gorrono L, Escriba T, Boulanger N et al. Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors. PLoS ONE 9(9), e106360 (2014).
MedlineGoogle Scholar
45. Egana-Gorrono L, Guardo AC, Bargallo ME et al. MicroRNA profile in CD8⁺ T-lymphocytes from HIV-infected individuals: relationship with antiviral immune response and disease progression. PLoS ONE 11(5), e0155245 (2016).
MedlineGoogle Scholar
46. Narla V, Bhakta N, Freedman JE et al. Unique circulating microRNA profiles in HIV infection. J. Acquir. Immune Defic. Syndr. 79(5), 644–650 (2018).
Medline CASGoogle Scholar
47. Seddiki N, Phetsouphanh C, Swaminathan S et al. The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection. Eur. J. Immunol. 43(2), 510–520 (2013).
Medline CASGoogle Scholar
48. Swaminathan S, Suzuki K, Seddiki N et al. Differential regulation of the Let-7 family of microRNAs in CD4⁺ T cells alters IL-10 expression. J. Immunol. 188(12), 6238–6246 (2012).
Medline CASGoogle Scholar
49. Witwer KW, Watson AK, Blankson JN, Clements JE. Relationships of PBMC microRNA expression, plasma viral load, and CD4⁺ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology 9, 5 (2012).
Medline CASGoogle Scholar
50. Yin L-B, Song C-B, Zheng J-F et al. Elevated expression of miR-19b enhances CD8(+) T cell function by targeting PTEN in HIV infected long term non-progressors with sustained viral suppression. Front. Immunol. 9, 3140 (2019).
MedlineGoogle Scholar
51. Yousefpouran S, Mostafaei S, Manesh PV et al. The assessment of selected MiRNAs profile in HIV, HBV, HCV, HIV/HCV, HIV/HBV co-infection and elite controllers for determination of biomarker. Microb. Pathog. 147, 104355 (2020).
Medline CASGoogle Scholar
52. Monteleone K, Selvaggi C, Cacciotti G et al. MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients. BMC Infect Dis. 15, 51 (2015).
MedlineGoogle Scholar
53. Munshi SU, Panda H, Holla P, Rewari BB, Jameel S. MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. PLoS ONE 9(5), e95920 (2014). • Reports for the first time that levels of miR-150 and miR-146b-5p are predictive of HIV/AIDS disease progression and therapy.
MedlineGoogle Scholar
54. Patel P, Ansari MY, Bapat S, Thakar M, Gangakhedkar R, Jameel S. The microRNA miR-29a is associated with human immunodeficiency virus latency. Retrovirology 11, 108 (2014).
MedlineGoogle Scholar
55. Pereira I de S, Maia MM, da Cruz AB et al. Plasma extracellular microRNAs are related to AIDS/cerebral toxoplasmosis co-infection. Parasite Immunol. 42(4), e12696 (2020). • Reports that gender could be an important factor in HIV-associated miRNAs.
MedlineGoogle Scholar
56. Thapa DR, Li X, Jamieson BD, Martinez-Maza O. Overexpression of microRNAs from the miR-17-92 paralog clusters in AIDS-related non-Hodgkin's lymphomas. PLoS ONE 6(6), e20781 (2011).
Medline CASGoogle Scholar
57. Ballegaard V, Ralfkiaer U, Pedersen KK et al. MicroRNA-210, microRNA-331, and microRNA-7 are differentially regulated in treated HIV-1-infected individuals and are associated with markers of systemic inflammation. J. Acquir. Immune Defic. Syndr. 74(4), e104–e113 (2017).
Medline CASGoogle Scholar
58. Jin C, Cheng L, Lu X, Xie T, Wu H, Wu N. Elevated expression of miR-155 is associated with the differentiation of CD8⁺ T cells in patients with HIV-1. Mol. Med. Rep. 16(2), 1584–1589 (2017).
Medline CASGoogle Scholar
59. Liu MQ, Zhao M, Kong WH et al. Antiretroviral therapy fails to restore levels of HIV-1 restriction miRNAs in PBMCs of HIV-1-infected MSM. Med. 94(46), e2116 (2015).
Medline CASGoogle Scholar
60. O'Meara T, Kong Y, Chiarella J et al. Exosomal microRNAs associate with neuropsychological performance in individuals with HIV infection on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 82(5), 514–522 (2019).
MedlineGoogle Scholar
61. Qi Y, Hu H, Guo H et al. MicroRNA profiling in plasma of HIV-1 infected patients: potential markers of infection and immune status. J. Public Heal. Emerg. 1(7), (2017).
Google Scholar
62. Squillace N, Bresciani E, Torsello A et al. Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients. J. Antimicrob. Chemother. 69(11), 3067–3075 (2014).
Medline CASGoogle Scholar
63. Balducci E, Leroyer AS, Lacroix R et al. Extracellular vesicles from T cells overexpress miR-146b-5p in HIV-1 infection and repress endothelial activation. Sci. Rep. 9(1), 10299 (2019).
MedlineGoogle Scholar
64. Biswas S, Haleyurgirisetty M, Lee S, Hewlett I, Devadas K. Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection. EBioMedicine 43, 307–316 (2019).
MedlineGoogle Scholar
65. Huang J, Lai J, Liang B et al. mircoRNA-3162-3p is a potential biomarker to identify new infections in HIV-1-infected patients. Gene 662, 21–27 (2018).
Medline CASGoogle Scholar
66. Low H, Hoang A, Pushkarsky T et al. HIV disease, metabolic dysfunction and atherosclerosis: a three year prospective study. PLoS ONE 14(4), e0215620 (2019).
Medline CASGoogle Scholar
67. Moghoofei M, Najafipour S, Mostafaei S et al. MicroRNAs profiling in HIV, HCV, and HIV/HCV co-infected patients. Curr. HIV Res. 19(1), 27–34 (2021).
Medline CASGoogle Scholar
68. Pacifici M, Delbue S, Ferrante P et al. Cerebrospinal fluid miRNA profile in HIV-encephalitis. J. Cell. Physiol. 228(5), 1070–1075 (2013).
Medline CASGoogle Scholar
69. Thapa DR, Bhatia K, Bream JH et al. B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas. AIDS 26(9), 1177–1180 (2012).
Medline CASGoogle Scholar
70. Thapa DR, Hussain SK, Tran WC et al. Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. J. Acquir. Immune Defic. Syndr. 66(2), 229–237 (2014).
Medline CASGoogle Scholar
71. Yelamanchili SV, Chaudhuri AD, Chen LN, Xiong H, Fox HS. MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis. 1, e77 (2010).
Medline CASGoogle Scholar
72. Zhou Y, Sun L, Wang X et al. Short Communication: HIV-1 infection suppresses circulating viral restriction microRNAs. AIDS Res. Hum. Retroviruses 32(4), 386–389 (2016).
Medline CASGoogle Scholar
73. McBride JA, Striker R. Imbalance in the game of T cells: what can the CD4/CD8 T-cell ratio tell us about HIV and health? PLoS Pathog. 13(11), e1006624 (2017).
MedlineGoogle Scholar
74. Yahyaei S, Biasin M, Saulle I et al. Identification of a specific miRNA profile in HIV-exposed seronegative individuals. J. Acquir. Immune Defic. Syndr. 73(1), 11–19 (2016).
Medline CASGoogle Scholar
75. Swaminathan S, Murray DD, Kelleher AD. miRNAs and HIV: unforeseen determinants of host-pathogen interaction. Immunol. Rev. 254(1), 265–280 (2013).
MedlineGoogle Scholar
76. Hunt EA, Broyles D, Head T, Deo SK. MicroRNA detection: current technology and research strategies. Annu. Rev. Anal. Chem. (Palo Alto). 8, 217–237 (2015).
Medline CASGoogle Scholar
77. Pimentel F, Bonilla P, Ravishankar YG et al. Technology in microRNA profiling: circulating microRNAs as noninvasive cancer biomarkers in breast cancer. J. Lab. Autom. 20(5), 574–588 (2015).
Medline CASGoogle Scholar
78. Benes V, Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50(4), 244–249 (2010).
Medline CASGoogle Scholar
79. Mathew R, Mattei V, Al Hashmi M, Tomei S. Updates on the current technologies for microRNA profiling. MicroRNA (Shariqah, UAE) 9, 17–24 (2019).
Google Scholar
80. Liu K, Tong H, Li T, Wang X, Chen Y. Research progress in molecular biology related quantitative methods of microRNA. Am. J. Transl. Res. 12(7), 3198–3211 (2020). • Reports on the recent advances in miRNA expression analysis.
Medline CASGoogle Scholar
81. Mujica ML, Gallay PA, Perrachione F et al. New trends in the development of electrochemical biosensors for the quantification of microRNAs. J. Pharm. Biomed. Anal. 189, 113478 (2020).
Medline CASGoogle Scholar
82. Detsika MG, Psarris A, Paraskevis D. MicroRNAs and HIV latency: a complex and promising relationship. AIDS Rev. 14(3), 188–94
MedlineGoogle Scholar
83. Schulte LN, Westermann AJ, Vogel J. Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids Res. 41(1), 542–553 (2013).
Medline CASGoogle Scholar
84. Chiang K, Sung TL, Rice AP. Regulation of cyclin T1 and HIV-1 replication by MicroRNAs in resting CD4⁺ T lymphocytes. J. Virol. 86(6), 3244–3252 (2012).
Medline CASGoogle Scholar
85. Wang X, Ye L, Hou W et al. Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood 113(3), 671–674 (2009).
Medline CASGoogle Scholar
86. Yuan Y, Liu L, Chen H et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell 29(5), 711–722 (2016).
Medline CASGoogle Scholar
87. Dai R, Ahmed SA. Sexual dimorphism of miRNA expression: a new perspective in understanding the sex bias of autoimmune diseases. Ther. Clin. Risk Manag. 10, 151–163 (2014).
Medline CASGoogle Scholar
88. Pasquereau S, Kumar A, Abbas W, Herbein G. Counteracting Akt activation by HIV protease inhibitors in monocytes/macrophages. Viruses 10(4), 190 (2018).
Google Scholar
89. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr. Top. Microbiol. Immunol. 346, 31–56 (2010).
Medline CASGoogle Scholar
90. Tybulewicz VLJ, Henderson RB. Rho family GTPases and their regulators in lymphocytes. Nat. Rev. Immunol. 9(9), 630–644 (2009).
Medline CASGoogle Scholar
91. Tavares LA, Januário YC, daSilva LLP. HIV-1 hijacking of host ATPases and GTPases that control protein trafficking. Front. Cell Dev. Biol. 9, 622610 (2021).
MedlineGoogle Scholar

Vol. 13, No. 20

Supplemental Materials

Metrics

Downloaded 117 times

History

Received 2 July 2021

Accepted 23 September 2021

Published online 25 October 2021

Published in print October 2021

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/epi-2021-0237

Author contributions

CG Leo, P Mincarone and S Sabina conceived and designed the study. CG Leo and P Mincarone developed the search string and retrieved selected works. CG Leo, P Mincarone, MR Tumolo, A Panico, M Guido, A Zizza, R Sedile and S Sabina screened the papers for eligibility and extracted data from the included studies. All the authors analyzed the data. CG Leo and P Mincarone worked on data synthesis with the contributions of S Sabina and R Guarino. CG Leo, P Mincarone and MR Tumolo drafted the manuscript. All the authors revised it critically. R Guarino managed the information system (software and databases) adopted in the review. All authors read and approved the final version for submission and are accountable for all aspects of the work.

Acknowledgments

The authors would like to thank D Moorthly, a methodologist-expert in information retrieval and systematic reviews, who provide suggestions to build the electronic search strategy and A Bodini for having provided precious suggestions for the organization of the manuscript.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download